Ambrx Biopharma moved -2.5% this morning session, trading between a high of $12.0 and a low of $11.3803 per share. Yesterday the stock finished at $11.7 per share.
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. The small-cap biotechnology: biological products (no diagnostic substances) company is based in the United States, and over the last twelve months it has returned a dividend yield of None%. Ambrx Biopharma has trailing twelve months earnings per share (EPS) of -2.29, which at today's prices amounts to a price to earnings (P/E) ratio of -5.0.
Based on its expected future earnings growth, the company has a price to earnings growth (PEG) ratio of -1.93. Usually a PEG ratio between zero and one indicates a potentially undervalued company.